Sustained response versus relapse: The pharmacotherapeutic goal for obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 313-322

  Fineberg, Naomi A ^a,b   Pampaloni, Ilenia ^a,c   Pallanti, Stefano ^c,d   Ipser, Jonathan ^e   Stein, Dan J ^e  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Long term treatment; Meta analysis; Obsessive compulsive disorder; Relapse prevention; Systematic review

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUVOXAMINE; PAROXETINE; PLACEBO; SERTRALINE;

CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZATION; RELAPSE; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CLOMIPRAMINE; FLUOXETINE; HUMANS; META-ANALYSIS AS TOPIC; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 34948897471     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32825ea312     Document Type: Review

References (63)

1. Angst J, Gamma A, Endrass J, Goodwin R, Ajdacic V, Eich D, et al. (2004). Obsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and course. Eur Arch Psychiatry Clin Neurosci 254:156-164.
2. Bailer DC, Burnham D, Oakes R (1995). Long-term treatment of outpatients with obsessive compulsive disorder; an extension of the companion study (Study no. MY-1053/BRL-029060/CPMS-127). http://ctr.gsk.co.uk/Summary/paroxetine/ studylist.asp
3. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596.
4. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006). What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428-1434.
5. Biondi M, Picardi A (2005). Increased maintenance of obsessive-compulsive disorder remission after integrated serotonergic treatment and cognitive psychotherapy compared with medication alone. Psychother Psychosom 74:123-128.
6. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, et al. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 5:17-30.
7. Cottraux J, Note I, Yao SN, Lafont S, Note B, Mollard E, et al. (2001). A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother Psychosom 70:288-297.
8. Dunbar G, Steiner M, Bushnell WD, Gergel I, Wheadon DE (1995). Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. Eur Neuropsychopharmacol 5:372(P-D-11).
9. DuPont RL, Rice DP, Shiraki S, Rowland CR. (1995). Economic costs of obsessive compulsive disorder. Med Interface 8:102-109.
10. Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-1030.
11. Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107-129.
12. Fineberg NA, Tonnoir B, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17:430-439.
13. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, et al. (1985). Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42:977-983.
14. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151-161.
15. Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, et al. (2001). Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebocontrolled clinical trial. J Am Acad Child Adolesc Psychiatry 40:773-779.
16. Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, et al. (2003). Impact of comorbidity on treatment response to paroxetine in paediatric obsessive compulsive disorder: is the use of exclusion criteria empirically supported in randomized controlled trials? J Child Adolesc Psychopharmacol 13 (Suppl):S19-29.
17. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989a). The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
18. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989b). Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 46:36-44.
19. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11:21-29.
20. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. (1995). A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10:57-65.
21. Greist JH, Bandelow B, Hollander E, Marazzitti D, Montgomery SA, Nutt DJ, et al. (2003). Long-term treatment of obsessive compulsive disorder in adults. CNS Spectrums 8:7-16.
22. Guy W(1976). In ECDEU assessment manual for psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office, US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD, National Institute of Mental Health.
23. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
24. Harvey BH, McEwen BS, Stein DJ (2003). Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry 54:1105-1117.
25. Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R (2001). Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry 179:324-329.
26. Hollander E, Wong C (1998). Psychosocial function and economic costs of obsessive compulsive disorder. CNS Spectrums 3 (5 Suppl 1):48-58.
27. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB (2003). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121.
28. Katz RJ, DeVeaugh-Geiss J, Landau P (1990). Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 28:401-404.
29. Kessler RC, Berglund P, Demler D, Jin R, Merikangas KR, Walters EE (2005a). Lifetime prevalence and age of onset distribution of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
30. Kessler RC, Demler D, Chiu WT, Walters EE (2005b). Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
31. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159:89-95.
32. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, et al. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19:172-176.
33. Leonard HL, Swedo S, Rapoport JL, Coffey M, Cheslow D (1988). Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 24:93-95.
34. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, et al. (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41:1431-1438.
35. Maina G, Albert U, Bogetto F (2001). Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:33-38.
36. Maina G, Albert U, Ziero S, Bogetto F (2003). Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18:23-29.
37. March JS, Frances A, Kahn DA, Carpenter D (1997). The Expert Consensus Guideline series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 58 (Suppl):1-72.
38. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752-1756.
39. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3:143-152.
40. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM (2001). Citalopram 20, 40 and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:75-86.
41. NICE: National Collaborating Centre for Mental Health (NCCMH) (2006). The NICE Guideline obsessive compulsive disorder and body dysmorphic disorder. The British Psychological Society and the Royal College of Psychiatrists, UK.
42. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. and the International Treatment-Refractory OCD Consortium (2002). Treatmentnon-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5:181-191.
43. Pato MT, Zohar-Kadouch R, Zohar J (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psychiatry 145:211-214.
44. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA (2006). The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 67:703-711.
45. Rasmussen S, Hackett E, Duboff E, Greist J, Halaris A, Koran LM, et al. (1997). A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12:309-316.
46. Ravizza L, Maina G, Bogetto F (1997). Episodic and chronic obsessive-compulsive disorder. Depress Anxiety 6:154-158.
47. Ravizza L, Maina G, Bogetto F, Albert U, Barzega G, Bellino S (1998). Long term treatment of obsessive compulsive disorder. CNS Drugs 10:47-255.
48. Review Manager (RevMan). [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
49. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, et al. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222-229.
50. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, et al. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949-958.
51. Romano S, Goodman WK, Tamura R, Gonzales J, Deltito J, DuPont R, et al. (2001). Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 21:46-52.
52. Rosenbaum JF, Fava M, Hoog S, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome; a randomised clinical trial. Biol Psychiatry 44:77-87.
53. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, et al. (2004). Post-treatment effects of exposure therapy versus clomipramine in OCD. Depress Anxiety 19:225-233.
54. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR (2006). Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 67:269-276.
55. Skoog G, Skoog I (1999). A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 56:121-127.
56. Stein D, Tonnoir B, Andersen EW, Fineberg N (2007). Escitalopram in the treatment of obsessive compulsive disorder: a randomized, placebo-controlled, fixed-dose, 24 week study. Curr Med Res Opin 23:701-711.
57. Tollefson G, Rampey A, Potvin J, Jenike MA, Rush AJ, Dominquez RA, et al. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry 51:559-567.
58. Van Oppen P, de Haan E, van Balkom AJ, Spinhoven P, Hoogduin K, van Dyck R (1995). Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther 33:379-390.
59. Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. (2006). Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113:91-95.
60. Wagner KD, Cook EH, Chung H, Messig M (2003). Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13 (Suppl 1):S53-S60.
61. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Chung-Kyoon-Lee M, et al. (1994). The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 55 (Suppl):5-10.
62. Yaryura-Tobias JA, Neziroglu F, Bergman L (1976). Chlorimipramine for obsessive compulsive neurosis: an organic approach. Curr Ther Res 20:541-548.
63. Zohar J, Judge R (1996). Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 169:468-474.